<DOC>
	<DOCNO>NCT02610868</DOCNO>
	<brief_summary>Multicenter , open-label , outpatient study safety effectiveness repeat dos MYOBLOC 1-year duration adult subject troublesome sialorrhea .</brief_summary>
	<brief_title>Open-Label Single-Arm Study MYOBLOC® Treatment Troublesome Sialorrhea Adults</brief_title>
	<detailed_description>Multicenter , open-label , outpatient study safety effectiveness repeat dos MYOBLOC 1-year duration adult subject troublesome sialorrhea . The primary goal determine long-term safety tolerability MYOBLOC ( administer intraglandularly single total dose 3,500 Units ) treatment every 13 week maximum possible duration 1 year adult subject troublesome sialorrhea . The secondary goal ass magnitude therapeutic response MYOBLOC ( administer intraglandularly single total dose 3,500 Units ) use effectiveness assessment perform interval treatment every 13 week maximum possible duration 1 year .</detailed_description>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<criteria>Seeking treatment troublesome sialorrhea least 3 month occur secondary disorder relate cause , include , limited , Parkinson 's Disease ( PD ) , adult cerebral palsy , amyotrophic lateral sclerosis ( ALS ) , stroke , traumatic brain injury , oral cancer , side effect medication . Able read provide write informed consent enrollment study , subject 's caregiver ( Legally Authorized Representative ) provide write informed consent . Male female , 18 85 year age ( inclusive ) . Minimum unstimulated salivary flow rate 0.2 g/min screen Minimum Investigator 's Drooling Frequency Severity Scale ( DFSS ) score 4 screening . Ability availability participate study 1 year ( ALS subject : ability availability participate study least 6 month ) , base overall health subject disease prognosis A moderate high risk aspiration exclude participation study . Subjects whose risk aspiration judge Investigator satisfactorily control placement PEG tube Gtube nutritional support eligible participate . Respiratory force vital capacity ( FVC ) &lt; 20 % predict Prior botulinum toxin type A B treatment salivary gland ( ) identify treatment study within 24 week screen . Prior botulinum toxin type A B treatment anatomical region select treatment study exclusionary , must occur least 12 week screen Subjects exclude , Investigator 's opinion , subject fail respond previous treatment botulinum toxin . Subjects receive plan receive botulinum toxin treatment , study drug ( MYOBLOC ) , entire course study ( point inform consent sign subject 's participation complete ) . Concomitant use , exposure within 5 halflives screen , aminoglycoside antibiotic , curarelike agent , agent interfere neuromuscular function Prior salivary gland surgery Current treatment treatment time study Coumadin® ( warfarin ) similar anticoagulant medication . Antiplatelet medication specifically exclusionary Evidence clinically significant neurologic disease Pregnancy lactation Anticipated schedule surgery study period . A PEG tube/G tube may place nutritional support time study exclude subject continue study participation . Major surgery ( require general anesthesia , except PEG tube/G tube placement ) within previous 6 month screen . Current infection sialorrhea treatment injection site ( ) History drug alcohol abuse currently within previous 6 month Participation another clinical drug , device , biological agent study within 30 day screen participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cerebral Palsy</keyword>
	<keyword>ALS</keyword>
	<keyword>Stroke</keyword>
	<keyword>Neuropletics</keyword>
</DOC>